Engaging with Bispecific T-Cell Engagers
Last Updated: May 16, 2025
An overview of how these agents’ function, their dosing schedules, notable side effects, and the Risk Evaluation and Mitigation Strategies (REMS) requirements for certain agents.
Find Similar Resources:
Immunotherapy
Immunotherapy
Immunotherapy
Immunotherapy
Example SOPs and Documents: Transitioning Patients on Bispecific T-Cell Engagers Between Care Settings
Last Updated: 07/20/2025
Example SOPs and Documents: Bispecific T-cell Engager Billing Procedure
Last Updated: 07/20/2025
Example SOPs and Documents: Bispecific T-Cell Engager Ordering and REMS Compliance
Last Updated: 07/20/2025
Example SOPs and Documents: On-Call Responsibilities for Nurses Managing Bispecific T-Cell Engagers
Last Updated: 07/20/2025
PQI in Action
PQI in Action
Immunotherapy
Immunotherapy
PQI in Action: Proactive Symptom Management in Myelofibrosis
Author: Cancer Specialists of North Florida
Last Updated: 07/20/2025
PQI in Action: Sonidegib (Odomzo®) Patient Management
Author: UCLA Medical Center | The Ohio State University Cancer Comprehensive Cancer Center (The James) | WVU Medicine
Last Updated: 07/20/2025
Example SOPs and Documents: Transitioning Patients on Bispecific T-Cell Engagers Between Care Settings
Last Updated: 07/20/2025
Example SOPs and Documents: Bispecific T-cell Engager Billing Procedure
Last Updated: 07/20/2025